LKFT — Lakefront Biotherapeutics
In 2026 Q2, 3 of the 140 tracked hedge funds reported a position in Lakefront Biotherapeutics (LKFT), worth $116.37M combined. Over the quarter 2 opened or added, 2 trimmed or exited.
Hedge fund holders, 2026 Q2
| Fund | Value | Portfolio % | Change |
|---|---|---|---|
| Madison Avenue | $103.37M | 4.40% | +39.9% |
| Renaissance | $12.23M | 0.02% | +29.3% |
| Monaco | $767.49K | 0.29% | -7% |
All stocks · Quarterly Trends · Hedge Fund Tracker
Source: SEC EDGAR 13F filings, reported as of quarter end and filed up to 45 days later. Not investment advice.